美国肝病研究协会（The American Association for the study of liver diseases，AASLD）第59次年会于2008年10月31日--11月4日在美国旧金山召开。丙型肝炎的抗病毒治疗和新型抗丙型肝炎病毒（HCV）药物的研究是本次大会病毒性肝炎研...美国肝病研究协会（The American Association for the study of liver diseases，AASLD）第59次年会于2008年10月31日--11月4日在美国旧金山召开。丙型肝炎的抗病毒治疗和新型抗丙型肝炎病毒（HCV）药物的研究是本次大会病毒性肝炎研究报告的主要内容之一。本文就此作如下主要介绍。展开更多
Infection with hepatitis C virus （HCV） affects approximately 170 million people worldwide. However, no vaccine or immunoglobulin is currently available for the prevention of HCV infection. The standard of care （SOC...Infection with hepatitis C virus （HCV） affects approximately 170 million people worldwide. However, no vaccine or immunoglobulin is currently available for the prevention of HCV infection. The standard of care （SOC） involving pegylated interferon-（] （PEG-IFN a） plus ribavirin （RBV） for 48 weeks results in a sustained virologic re- sponse in less than 50% of patients with chronic hepatitis C genotype 1, the most prevalent type of HCV in North America and Europe. Recently, reliable in vitro culture systems have been developed for accelerating antiviral therapy research, and many new specifically targeted antiviral therapies for hepatitis C （STAT-C） and treatment strategies are being evaluated in clinical trials. These new antiviral agents are expected to improve present treatment significantly and may potentially shorten treatment duration. The aim of this review is to summarize the current developments in new anti-HCV drugs.展开更多
文摘美国肝病研究协会（The American Association for the study of liver diseases，AASLD）第59次年会于2008年10月31日--11月4日在美国旧金山召开。丙型肝炎的抗病毒治疗和新型抗丙型肝炎病毒（HCV）药物的研究是本次大会病毒性肝炎研究报告的主要内容之一。本文就此作如下主要介绍。
基金Project partially supported by the Centers for Oceans and Human Health Program of the National Institute of Environmental Health Sciences (No.P50ES012740)the National Science Foundation of USA (Nos.OCE04-32479 and OCE09-11000)the National Mega Project on Major Drug Development of China (No.2011ZX09401-302)
文摘Infection with hepatitis C virus （HCV） affects approximately 170 million people worldwide. However, no vaccine or immunoglobulin is currently available for the prevention of HCV infection. The standard of care （SOC） involving pegylated interferon-（] （PEG-IFN a） plus ribavirin （RBV） for 48 weeks results in a sustained virologic re- sponse in less than 50% of patients with chronic hepatitis C genotype 1, the most prevalent type of HCV in North America and Europe. Recently, reliable in vitro culture systems have been developed for accelerating antiviral therapy research, and many new specifically targeted antiviral therapies for hepatitis C （STAT-C） and treatment strategies are being evaluated in clinical trials. These new antiviral agents are expected to improve present treatment significantly and may potentially shorten treatment duration. The aim of this review is to summarize the current developments in new anti-HCV drugs.
